At the news
? BULLISHIMPACT 6/10 6-K filed Jul 13, 2026 at 06:29 ET
GSK announced positive interim results from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in dMMR/MSI-H locally advanced rectal cancer. The trial met its primary objective, showing a sustained clinical complete response rate at 12 months (cCR12), supporting the potential to eliminate or delay chemotherapy, radiation, and surgery. GSK plans to share data with global regulators, including accelerated review in the US, where Jemperli already has Breakthrough Therapy and Fast Track designations.
- AZUR-1 phase II trial (n=154) met primary endpoint: sustained clinical complete response at 12 months (cCR12) in dMMR/MSI-H locally advanced rectal cancer
- Results support potential for Jemperli to become first immunotherapy to eliminate need for chemotherapy, radiation, and surgery in some patients
- Data to be shared with health authorities for regulatory review, including accelerated review in the US
- Jemperli already has Breakthrough Therapy and Fast Track designations from FDA in this setting
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access